Live Streaming
The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations
Hosted by Medscape, LLC
May 21, 2026 – Jun 18, 2026 Online / Virtual
About This Event
This activity provides clinicians with a deep dive into emerging phase 2/3 data on metastatic hormone-sensitive prostate cancer (mHSPC) treatment intensification. Learners will gain practical guidance on managing toxicity, drug-drug interactions, and risk-based therapy selection when transitioning from traditional monotherapy to evidence-based doublet and triplet combinations.
Sign in to unlock everything networkED.global adds to this event
We enrich every event with details scattered across the web — organized, verified, in one place:
- Earning CE? CE credits, accreditation, and which licenses it counts toward — tracked automatically.
- Speaking? Call-for-proposal deadlines and submission details.
- Exhibiting or sponsoring? Exhibit and sponsorship opportunities.
- Hosting events? Be connected directly to your target audiences.
Plus full agenda, pricing, registration, contacts, and topics covered.